EOLS News and Press, Evolus Inc. From 08/05/25

Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse ™ and Continued Strength in International Markets Evolysse ™ Delivered $9.7 Million i...

SOPHiA GENETICS SA (SOPH) is expected to report for Q2 2025 Investors Title Company (ITIC) is expected to report for Q2 2025 Safehold Inc. (SAFE) is expected to report $0.39 for Q2 2025 First Guaranty Bancshares Inc. (FGBI) is expected to report $-0.2 for Q2 2025 United Fire Group...

Evolus Inc. (EOLS) is expected to report $-0.18 for Q2 2025

First head-to-head study of four United States (U.S.) Food & Drug Administration (FDA) approved neurotoxins: Jeuveau ® , Botox ® , Dysport ® , and Xeomin ® The study published in JAMA Dermatology supports fast onset, strong peak effect, and long dur...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close. Evolus management w...

2025-07-21 17:20:30 ET Investment Overview I have covered Evolus ( EOLS ) twice before in notes for Seeking Alpha, the first time in March 2024 , issuing a "Buy" recommendation, and re-iterating that rating in a more recent note, in January this year. Shares are in fact ...

Launching into this key growth market 1 as part of the company’s geographic expansion strategy Evolus to provide Nuceiva ® to French medical aesthetics healthcare professionals through its partnership with Symatese enabling direct order and delivery Evo...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs...

2025-06-10 10:08:14 ET Investment Thesis I've been keeping a close eye on Phathom Pharmaceuticals, Inc. ( PHAT ) for quite some time. I like what they do; their main focus is on gastrointestinal disorders, and they have a pretty promising drug to handle them. "Voquezna," as ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: Evolysse ™ Recognized as the Best Filler for 2025 with its recently...